Open an account

Artelo Biosciences

ARTL · NASDAQ

$2.62−$0.04 (−1.50%)TodayMarket closed ·
Prev close $2.66

About ARTL

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 7 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Employees
7
Headquarters
Solana Beach, California
Listed
Oct 13, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
artelobio.com

ARTL key statistics

Market cap
1.44M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.37M
Volume
26.28K
Open price
$2.70
High today
$2.80
Low today
$2.62
52 Week high
$179.19
52 Week low
$2.66

Artelo Biosciences (ARTL) at a glance

Artelo Biosciences (ARTL) last traded at $2.62, with a market cap of 1.44M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.62 and $2.80. The current price is 0.0% above the day's low and 6.4% below its high.

Volume so far is 26.28K shares, below the average of 1.37M shares a day.

Over the past year Artelo Biosciences has ranged from $2.66 to $179.19, and now sits 0% of the way up that range.

Artelo Biosciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.89 per share against an estimate of $0.00.

The average analyst price target is $30.60, 1067.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $30.60
Low
$30.30
Now
$2.62
High
$31.50

ARTL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 45.5% on average.

  1. Q2 FY24: reported -$121.50 per share against an estimate of -$139.90
  2. Q3 FY24: reported -$56.70 per share against an estimate of -$76.56
  3. Q4 FY24: reported -$189.54 per share against an estimate of -$72.16
  4. Q1 FY25: reported -$116.64 per share against an estimate of -$21.48
  5. Q2 FY25: reported -$151.47 per share against an estimate of -$115.39
  6. Q3 FY25: reported -$107.19 per share against an estimate of -$22.58
  7. Q4 FY25: reported -$1.08 per share against an estimate of -$43.24
  8. Q2 FY26: reported -$0.89 per share against an estimate of $0.00

ARTL news

  • Avi Kapoor

    Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000

  • Henry Khederian

    Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Vandana Singh

    Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

  • Avi Kapoor

    Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results

  • Avi Kapoor

    Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results

Similar companies

Companies in the same industry as Artelo Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.